Michael J Birrer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/700580/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nature Reviews Cancer, 2015, 15, 668-679.	28.4	839
2	Inherited Mutations in Women With Ovarian Carcinoma. JAMA Oncology, 2016, 2, 482.	7.1	576
3	Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncology, The, 2014, 15, 1207-1214.	10.7	523
4	Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet, The, 2017, 390, 1654-1663.	13.7	424
5	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	21.4	356
6	ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells. Genes and Development, 2017, 31, 318-332.	5.9	307
7	Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer. New England Journal of Medicine, 2016, 374, 738-748.	27.0	303
8	Antibody-Drug Conjugate-Based Therapeutics: State of the Science. Journal of the National Cancer Institute, 2019, 111, 538-549.	6.3	257
9	Deep, noninvasive imaging and surgical guidance of submillimeter tumors using targeted M13-stabilized single-walled carbon nanotubes. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 13948-13953.	7.1	221
10	CXCL12/CXCR4 Blockade Induces Multimodal Antitumor Effects That Prolong Survival in an Immunocompetent Mouse Model of Ovarian Cancer. Cancer Research, 2011, 71, 5522-5534.	0.9	206
11	Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncology, The, 2019, 20, 570-580.	10.7	191
12	Risk Prediction for Late-Stage Ovarian Cancer by Meta-analysis of 1525 Patient Samples. Journal of the National Cancer Institute, 2014, 106, .	6.3	184
13	Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody–Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. Journal of Clinical Oncology, 2017, 35, 1112-1118.	1.6	158
14	Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential. Nature Communications, 2014, 5, 5092.	12.8	112
15	Comparative Meta-analysis of Prognostic Gene Signatures for Late-Stage Ovarian Cancer. Journal of the National Cancer Institute, 2014, 106, .	6.3	110
16	Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance. Journal of Clinical Investigation, 2017, 128, 589-606.	8.2	105
17	Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma. Gynecologic Oncology, 2015, 136, 246-253.	1.4	104
18	Early tumor detection afforded by inÂvivo imaging of near-infrared II fluorescence. Biomaterials, 2017, 134, 202-215.	11.4	100

#	Article	IF	CITATIONS
19	A functional variant in <i>HOXA11-AS</i> , a novel long non-coding RNA, inhibits the oncogenic phenotype of epithelial ovarian cancer. Oncotarget, 2015, 6, 34745-34757.	1.8	98
20	Phase 1 doseâ€escalation study of mirvetuximab soravtansine (<scp>IMGN853</scp>), a folate receptor αâ€ŧargeting antibodyâ€drug conjugate, in patients with solid tumors. Cancer, 2017, 123, 3080-3087.	4.1	94
21	Somatic Mosaic Mutations in <i>PPM1D</i> and <i>TP53</i> in the Blood of Women With Ovarian Carcinoma. JAMA Oncology, 2016, 2, 370.	7.1	88
22	Maximizing Synergistic Activity When Combining RNAi and Platinum-Based Anticancer Agents. Journal of the American Chemical Society, 2017, 139, 3033-3044.	13.7	74
23	Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses. Journal of the National Cancer Institute, 2017, 109, .	6.3	74
24	Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine. Gynecologic Oncology, 2017, 147, 402-407.	1.4	73
25	Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer. Nature Communications, 2017, 8, 2166.	12.8	71
26	Translational Impact of Nanoparticle–Drug Conjugate CRLX101 with or without Bevacizumab in Advanced Ovarian Cancer. Clinical Cancer Research, 2015, 21, 808-818.	7.0	70
27	A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer. Gynecologic Oncology, 2016, 142, 62-69.	1.4	70
28	Real-Time Single-Walled Carbon Nanotube-Based Fluorescence Imaging Improves Survival after Debulking Surgery in an Ovarian Cancer Model. ACS Nano, 2019, 13, 5356-5365.	14.6	70
29	Creation of a Human Secretome: A Novel Composite Library of Human Secreted Proteins: Validation Using Ovarian Cancer Gene Expression Data and a Virtual Secretome Array. Clinical Cancer Research, 2015, 21, 4960-4969.	7.0	62
30	An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience. Gynecologic Oncology, 2017, 147, 243-249.	1.4	61
31	A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer. Future Oncology, 2018, 14, 123-136.	2.4	60
32	Targeting the Nuclear Import Receptor Kpnβ1 as an Anticancer Therapeutic. Molecular Cancer Therapeutics, 2016, 15, 560-573.	4.1	57
33	FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer. Future Oncology, 2018, 14, 1669-1678.	2.4	55
34	Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. Gynecologic Oncology, 2018, 151, 46-52.	1.4	48
35	Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer. Anticancer Research, 2014, 34, 811-817.	1.1	46
36	AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E4418-27.	7.1	45

#	Article	IF	CITATIONS
37	Anticancer Immunotherapy by MFAP5 Blockade Inhibits Fibrosis and Enhances Chemosensitivity in Ovarian and Pancreatic Cancer. Clinical Cancer Research, 2019, 25, 6417-6428.	7.0	39
38	Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody–Drug Conjugate Mirvetuximab Soravtansine. Clinical Cancer Research, 2019, 25, 1727-1736.	7.0	39
39	CD44 Splice Variant v8-10 as a Marker of Serous Ovarian Cancer Prognosis. PLoS ONE, 2016, 11, e0156595.	2.5	38
40	Methods for Systematic Identification of Membrane Proteins for Specific Capture of Cancer-Derived Extracellular Vesicles. Cell Reports, 2019, 27, 255-268.e6.	6.4	38
41	Biomarkers in ovarian cancer: To be or not to be. Cancer, 2019, 125, 4563-4572.	4.1	38
42	Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors. Clinical Cancer Research, 2018, 24, 2749-2757.	7.0	37
43	Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer. Oncotarget, 2015, 6, 44551-44562.	1.8	37
44	Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma. Clinical Cancer Research, 2018, 24, 3928-3940.	7.0	35
45	"Carcinosarcoma of the ovary, fallopian tube, and peritoneum: Prognostic factors and treatment modalities― Gynecologic Oncology, 2016, 142, 248-254.	1.4	34
46	The Impact of Stroma Admixture on Molecular Subtypes and Prognostic Gene Signatures in Serous Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 509-519.	2.5	34
47	Phase II, 2â€stage, 2â€arm, PIK3CA mutation stratified trial of MKâ€2206 in recurrent endometrial cancer. International Journal of Cancer, 2020, 147, 413-422.	5.1	31
48	Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218. Clinical Cancer Research, 2020, 26, 1288-1296.	7.0	29
49	ISG15 Promotes ERK1 ISGylation, CD8+ T Cell Activation and Suppresses Ovarian Cancer Progression. Cancers, 2018, 10, 464.	3.7	28
50	High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study. Gynecologic Oncology, 2017, 146, 247-253.	1.4	23
51	Primordial germ cells as a potential shared cell of origin for mucinous cystic neoplasms of the pancreas and mucinous ovarian tumors. Journal of Pathology, 2018, 246, 459-469.	4.5	23
52	Overexpression of enhance of Zeste homolog 2 (EZH2) in endometrial carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. Gynecologic Oncology, 2020, 156, 423-429.	1.4	23
53	Comparing Platforms for Messenger RNA Expression Profiling of Archival Formalin-Fixed, Paraffin-Embedded Tissues. Journal of Molecular Diagnostics, 2015, 17, 374-381.	2.8	22
54	Phase II, two-stage, two-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer (EC) Journal of Clinical Oncology, 2013, 31, 5524-5524.	1.6	22

#	Article	IF	CITATIONS
55	Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology, 2016, 141, 43-48.	1.4	21
56	Dysregulation of miR-181c expression influences recurrence of endometrial endometrioid adenocarcinoma by modulating NOTCH2 expression: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology, 2017, 147, 648-653.	1.4	21
57	Inhibition of the Wnt/β-catenin pathway enhances antitumor immunity in ovarian cancer. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592091379.	3.2	21
58	Molecular Subtypes of High-Grade Serous Ovarian Cancer: The Holy Grail?. Journal of the National Cancer Institute, 2014, 106, .	6.3	18
59	The DoppelgÃ ¤ ger Effect: Hidden Duplicates in Databases of Transcriptome Profiles. Journal of the National Cancer Institute, 2016, 108, djw146.	6.3	18
60	Retrospective analysis of candidate predictive tumor biomarkers (BMs) for efficacy in the GOG-0218 trial evaluating front-line carboplatin–paclitaxel (CP) ± bevacizumab (BEV) for epithelial ovarian cancer (EOC) Journal of Clinical Oncology, 2015, 33, 5505-5505.	1.6	18
61	Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer. Gynecologic Oncology Reports, 2019, 29, 118-122.	0.6	17
62	Spleen Tyrosine Kinase Confers Paclitaxel Resistance in Ovarian Cancer. Cancer Cell, 2015, 28, 7-9.	16.8	15
63	Sustained, low-dose intraperitoneal cisplatin improves treatment outcome in ovarian cancer mouse models. Journal of Controlled Release, 2015, 220, 358-367.	9.9	15
64	Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology—Gynecologic Oncology Group Study 240 (NCT 00803062). Molecular Cancer Therapeutics, 2020, 19, 2363-2370.	4.1	15
65	Integrated genomic analysis of clear cell ovarian cancers identified PRKCI as a potential therapeutic target. Oncotarget, 2017, 8, 96482-96495.	1.8	15
66	Extended carboplatin infusion does not reduce frequency of hypersensitivity reaction at initiation of retreatment in patients with recurrent platinum-sensitive ovarian cancer. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 177-178.	3.8	14
67	Making a Difference: Distinguishing Two Primaries From Metastasis in Synchronous Tumors of the Ovary and Uterus. Journal of the National Cancer Institute, 2015, 108, djv442.	6.3	13
68	Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations. Oncologist, 2018, 23, 697-703.	3.7	12
69	Phase 1 study of IMGN853, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) in patients (Pts) with epithelial ovarian cancer (EOC) and other FRA-positive solid tumors Journal of Clinical Oncology, 2015, 33, 5558-5558.	1.6	12
70	A phase I, first-in-human study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of IMGN853 in patients (Pts) with epithelial ovarian cancer (EOC) and other FOLR1-positive solid tumors Journal of Clinical Oncology, 2013, 31, 2573-2573.	1.6	11
71	A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer Journal of Clinical Oncology, 2014, 32, LBA5500-LBA5500.	1.6	11
72	Phase 1 Study of Monotherapy with KHK2866, an Anti-Heparin-Binding Epidermal Growth Factor-Like Growth Factor Monoclonal Antibody, in Patients with Advanced Cancer. Targeted Oncology, 2016, 11, 317-327.	3.6	10

#	Article	IF	CITATIONS
73	Overall survival and updated progression-free survival results from a randomized phase 2 trial comparing the combination of olaparib and cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer Journal of Clinical Oncology, 2017, 35, 5535-5535.	1.6	9
74	A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer Journal of Clinical Oncology, 2014, 32, LBA5500-LBA5500.	1.6	8
75	A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology, 2017, 144, 101-106.	1.4	7
76	Toward Improving Practices for Submission of Diagnostic Tissue Blocks for National Cancer Institute Clinical Trials. American Journal of Clinical Pathology, 2020, 153, 149-155.	0.7	7
77	Preliminary single agent activity of IMGN853, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Phase I trial Journal of Clinical Oncology, 2015, 33, 5518-5518.	1.6	7
78	A phase I study of bevacizumab in combination with niraparib in patients with platinum-sensitive epithelial ovarian cancer: The ENGOT-OV24/AVANOVA1 trial Journal of Clinical Oncology, 2016, 34, 5555-5555.	1.6	7
79	Mirvetuximab soravtansine (IMGN853), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Activity and safety analyses in phase I pooled expansion cohorts Journal of Clinical Oncology, 2017, 35, 5547-5547.	1.6	7
80	Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology, 2017, 147, 396-401.	1.4	6
81	A phase 1b, open-label, non-randomized multicenter study of birinapant in combination with conatumumab in subjects with relapsed epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. Journal of Clinical Oncology, 2015, 33, 5571-5571.	1.6	6
82	Phase 2, two-group, two-stage, open-label study of avelumab in patients with microsatellite stable, microsatellite instable and <i>POLE</i> -mutated recurrent or persistent endometrial cancer Journal of Clinical Oncology, 2017, 35, TPS5615-TPS5615.	1.6	6
83	Opsalin: A phase II placebo (Pbo)-controlled randomized study of ombrabulin in patients with platinum-sensitive recurrent ovarian cancer (OC) treated with carboplatin (Cb) and paclitaxel (P) Journal of Clinical Oncology, 2013, 31, 5516-5516.	1.6	5
84	Prognostic and predictive blood-based biomarkers (BMs) in patients (pts) with advanced epithelial ovarian cancer (EOC) treated with carboplatin–paclitaxel (CP) ± bevacizumab (BEV): Results from GOG-0218 Journal of Clinical Oncology, 2016, 34, 5521-5521.	1.6	5
85	Safety findings from FORWARD II: A Phase 1b study evaluating the folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) mirvetuximab soravtansine (IMGN853) in combination with bevacizumab, carboplatin, pegylated liposomal doxorubicin (PLD), or pembrolizumab in patients (pts) with ovarian cancer Journal of Clinical Oncology 2017 35 5553-5553	1.6	5
86	Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study. Gynecologic Oncology, 2017, 146, 137-145.	1.4	4
87	Ovarian cancer: individualized and personalized care. Expert Review of Obstetrics and Gynecology, 2010, 5, 409-419.	0.4	3
88	Ovarian Cancer: Targeting the Untargetable. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , 13-15.	3.8	3
89	Variation in resource utilization associated with the surgical management of ovarian cancer. Gynecologic Oncology, 2019, 152, 587-593.	1.4	3
90	IMGN853 (mirvetuximab soravtansine), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC): Single-agent activity in platinum-resistant epithelial ovarian cancer (EOC) patients (pts) Journal of Clinical Oncology, 2016, 34, 5567-5567.	1.6	3

#	Article	IF	CITATIONS
91	A randomized, open-label, phase II study of anti-NaPi2b antibody-drug conjugate (ADC) lifastuzumab (Lifa) vedotin (DNIB0600A) compared to pegylated liposomal doxorubicin (PLD) in patients (pts) with platinum-resistant ovarian cancer (PROC) Journal of Clinical Oncology, 2016, 34, 5569-5569.	1.6	3
92	FORWARD I (GOG 3011): A randomized phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian cancer (EOC), primary peritoneal cancer, or primary fallopian tube cancer Journal of Clinical Oncology, 2017, 35, TPS5607-TPS5607.	1.6	3
93	Risk stratification after recurrence of human papillomavirus (HPV) â€related and nonâ€HPV â€related oropharyngeal cancer: A secondary analysis of NRG Oncology RTOG 0129 and 0522. Head and Neck, 2021, 44, 158.	2.0	3
94	Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinumâ€sensitive ovarian, fallopian tube, or primary peritoneal cancer. Cancer, 2016, 122, 3297-3306.	4.1	2
95	OPSALIN: A phase II placebo-controlled randomized study of ombrabulin in patients with platinum-sensitive recurrent ovarian cancer treated with carboplatin (Cb) and paclitaxel (P) Journal of Clinical Oncology, 2012, 30, TPS5112-TPS5112.	1.6	2
96	A phase 1 study optimizing the dosing of olaparib tablet formulation combined with cediranib in recurrent ovarian cancer Journal of Clinical Oncology, 2015, 33, 5559-5559.	1.6	2
97	Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study Journal of Clinical Oncology, 2015, 33, 5592-5592.	1.6	2
98	A snapshot of potentially personalized care: Molecular diagnostics in gynecologic cancer Journal of Clinical Oncology, 2012, 30, 5029-5029.	1.6	1
99	An evaluation of survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: A Gynecologic Oncology Group experience Journal of Clinical Oncology, 2013, 31, 5534-5534.	1.6	1
100	Real-time single-walled nanotube (SWNT)-based imaging system to improve tumor detection and survival in ovarian cancer preclinical model Journal of Clinical Oncology, 2016, 34, 5530-5530.	1.6	1
101	Targeting VEGFRi resistance through HIF-1Ã _i suppression: Phase II clinical trial evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent platinum resistant ovarian cancer Journal of Clinical Oncology, 2015, 33, TPS5614-TPS5614.	1.6	1
102	Ovarian Cancer Maintenance: Practice hanging Data Calls for Changing Practice. Oncologist, 2019, 24, 576-579.	3.7	0
103	Achieving quality: Comparing recommendations for cancer care between NCCN and ESMO Journal of Clinical Oncology, 2013, 31, 6579-6579.	1.6	Ο
104	A phase I/II trial of multiple dose VB-111 and weekly paclitaxel in recurrent platinum-resistant Müllerian cancer Journal of Clinical Oncology, 2015, 33, 5542-5542.	1.6	0
105	The value of TOP2A as a target for anthracycline-based chemotherapy in advanced endometrial carcinoma (EC): NRG Oncology/Gynecology Oncology Group study Journal of Clinical Oncology, 2015, 33, e16509-e16509.	1.6	Ο
106	Tumor responses and preliminary survival data in a phase II trial of ofranergene obadenovec (VB-111) combined with paclitaxel in patients with recurrent platinum resistant ovarian cancer Journal of Clinical Oncology, 2016, 34, 5551-5551.	1.6	0
107	Quality of life among long-term ovarian cancer survivors Journal of Clinical Oncology, 2016, 34, e21570-e21570.	1.6	Ο
108	The morbidity and mortality conference (MMC) concept applied to contemporary oncology practice: Retrospective findings on management of 233 patients (pts) who died of ovarian cancer (OC), colorectal cancer (CRC), and wild-type (no identified targetable mutation) nonsquamous non-small cell lung cancer (WTLC) Journal of Clinical Oncology, 2017, 35, 241-241.	1.6	0

#	Article	IF	CITATIONS
109	Clinical characterization of long term survivors (LTS) in ovarian cancer (OC): Results of a propensity score matched (PSM) analysis of the international prospective tumor bank for ovarian cancer (TOC) Tj ETQq1 1 (0.7 &4 314	rg & T /Overlo
110	Harnessing IMGN853-mediated cell cytoxicity response by modulating FRα expression in ovarian cancer Journal of Clinical Oncology, 2017, 35, e17061-e17061.	1.6	0
111	The morbidity and mortality conference (MMC) concept applied to contemporary oncology practice: Retrospective findings on management of 233 patients (pts) who died of ovarian cancer (OC), colorectal cancer (CRC) and wild-type (no identified targetable mutation) nonsquamous non-small cell lung cancer (WTLC) lournal of Clinical Oncology. 2017. 35. e18195-e18195.	1.6	0